About iMMCO Diagnostics
iMMCO Diagnostics is a Healthcare company based in Buffalo (United States) founded in 1971, and was acquired by Trinity Biotech in July 2013. Diagnostic solutions for autoimmune disorders are developed and distributed. The company has 78 employees. Its focus areas include Life Sciences, Immunology, In Vitro Diagnostic Tests and Rheumatoid Arthritis. Its legal entity is IMMCO DIAGNOSTICS, INC. Its competitors include Crescendo Bioscience, Selventa and Cytonics; 3 of its 3 listed competitors have raised funding.
Company details
IMMCO Diagnostics is a provider of diagnostic solutions for autoimmune disorders. It develops and distributes autoimmune disease diagnostics devices and lab services to the market. Products include IFA ImmuGlo, Mardx, ImmuLisa, Captia (EIA), ImmuBlot, Marstripe, ImmcoStripe (line immunoassays), and Amerlex . The platform offers biopsy, serology, and other test services for the diagnosis of autoimmune disorders and related immunological conditions such as thyroiditis, rheumatoid arthritis, type 1 diabetes, coeliac disease, ulcerative colitis, Crohns disease, systemic lupus erythematosus, and scleroderma systemic sclerosis. It also provides diagnostic solutions for infectious disease, hemoglobins, autoimmune, antibodies, urinalysis, and more.
- Headquarters Buffalo, United States
- Employees 78
- Stage Acquired
- SectorsHealthcare
- Website immcodiagnostics.com
- Social LinkedIn
- Acquired by Trinity Biotech (Jul 2013)
- Legal Name Immco Diagnostics, Inc
- InvestorsTrinity Biotech
& 1 more
- Employee Count78
- Acquired byTrinity Biotech
(Jul 2013)
Funding Insights of iMMCO Diagnostics
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of iMMCO Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2007 | Private Equity Round | – | – |
2 investors in total: 2 institutional.
Investors in iMMCO Diagnostics
iMMCO Diagnostics has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Trinity Biotech and Summit Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Summit Partners is recognized as a growth equity investment firm. | summitpartners.com | Boston, United States | ||
Provider of In vitro diagnostic kits for clinical labs | 1992 | trinitybiotech.com | Bray, Ireland |
Investor details for iMMCO Diagnostics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of iMMCO Diagnostics
3 dated milestones of iMMCO Diagnostics across 42 years, from founding to its latest funding, stage changes and deals.
- Founded iMMCO Diagnostics is founded.
- Funding First funding round.
- Exit Acquired by Trinity Biotech.
Competitors of iMMCO Diagnostics
iMMCO Diagnostics has 3 listed competitors in our database, 3 of them funded. They include Crescendo Bioscience, Selventa and Cytonics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| crescendobio.com | 2002 | San Francisco, United States | $122.05M | 128 | Molecular tests for autoimmune and inflammatory diseases are provided. | |
| selventa.com | 2001 | Cambridge, United States | $11.96M | Selventa specializes in diagnostics for personalized medicine, advancing tailored healthcare solutions. | ||
| cytonics.com | 2006 | Jupiter, United States | $3.33M | 8 | Diagnostics and therapeutics for osteoarthritis are developed. |
Detailed competitors of iMMCO Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as iMMCO Diagnostics (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about iMMCO Diagnostics
iMMCO Diagnostics was founded in 1971 and raised its 1st funding round 36 years after it was founded.
iMMCO Diagnostics is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
iMMCO Diagnostics has 78 employees.
IMMCO Diagnostics is a provider of diagnostic solutions for autoimmune disorders. It develops and distributes autoimmune disease diagnostics devices and lab services to the market. Products include IFA ImmuGlo, Mardx, ImmuLisa, Captia (EIA), ImmuBlot, Marstripe, ImmcoStripe (line immunoassays), and Amerlex . The platform offers biopsy, serology, and other test services for the diagnosis of autoimmune disorders and related immunological conditions such as thyroiditis, rheumatoid arthritis, type 1 diabetes, coeliac disease, ulcerative colitis, Crohns disease, systemic lupus erythematosus, and scleroderma systemic sclerosis. It also provides diagnostic solutions for infectious disease, hemoglobins, autoimmune, antibodies, urinalysis, and more.
iMMCO Diagnostics's top competitors include Cytonics, Crescendo Bioscience and Selventa.
iMMCO Diagnostics has 2 investors. Key investors include Trinity Biotech, and Summit Partners.
iMMCO Diagnostics operates through Immco Diagnostics, Inc.
Yes. iMMCO Diagnostics was acquired by Trinity Biotech in July 2013.